Hypomethylation of LINE-1 in primary tumor has poor prognosis in young breast cancer patients: A retrospective cohort study

Breast Cancer Research and Treatment

Volumn 134, Issue 3, 2012, Pages 1103-1114

  Van Hoesel, Anneke Q ^a,b   Van De Velde, Cornelis J H ^b   Kuppen, Peter J K ^b   Liefers, Gerrit Jan ^b   Putter, Hein ^b   Sato, Yusuke ^a   Elashoff, David A ^c   Turner, Roderick R ^a   Shamonki, Jaime M ^a   De Kruijf, Esther M ^b   Van Nes, Johanna G H ^b   Giuliano, Armando E ^a   Hoon, Dave S B ^a  

^a JOHN WAYNE CANCER INSTITUTE   (United States)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Age; Breast cancer; LINE 1; Methylation; Prognosis

Indexed keywords

ADULT; ALLELE; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER INVASION; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DNA METHYLATION; FEMALE; HUMAN; HUMAN TISSUE; INTRADUCTAL CARCINOMA; LONG INTERSPERSED REPEAT; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; ONSET AGE; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; POSTMENOPAUSE; PREMENOPAUSE; PRIMARY TUMOR; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADULT; AGE FACTORS; BREAST NEOPLASMS; CELL TRANSFORMATION, NEOPLASTIC; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; DNA METHYLATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LONG INTERSPERSED NUCLEOTIDE ELEMENTS; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84868211985     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-012-2038-0     Document Type: Article

References (51)

1. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55(2):74-108
2. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365(9472):1687-1717
3. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, Somerfield MR, Hayes DF, Bast RC Jr (2007) American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25(33):5287-5312
4. Herman JG, Baylin SB (2003) Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 349(21):2042-2054
5. Mulero-Navarro S, Esteller M (2008) Epigenetic biomarkers for human cancer: the time is now. Crit Rev Oncol Hematol 68(1):1-11
6. Kristensen LS, Nielsen HM, Hansen LL (2009) Epigenetics and cancer treatment. Eur J Pharmacol 625 (1-3):131-142
7. Lane AA, Chabner BA (2009) Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 27(32):5459-5468
8. Sausville EA, Carducci MA (2005) Making bad cells go good: the promise of epigenetic therapy. J Clin Oncol 23(17):3875-3876
9. Esteller M (2008) Epigenetics in cancer. N Engl J Med 358(11):1148-1159
10. Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, Devon K, Dewar K, Doyle M, Fitz Hugh W et al (2001) Initial sequencing and analysis of the human genome. Nature 409(6822):860-921
11. St Laurent G 3rd, Hammell N, McCaffrey TA (2010) A LINE-1 componentto human aging:doLINE elements exactalongevity cost for evolutionary advantage? Mech Ageing Dev 131(5):299-305
12. Beck CR, Collier P, Macfarlane C, Malig M, Kidd JM, Eichler EE, Badge RM, Moran JV (2010) LINE-1 retrotransposition activity in human genomes. Cell 141(7):1159-1170
13. Wolff EM, Byun HM, Han HF, Sharma S, Nichols PW, Siegmund KD, Yang AS, Jones PA, Liang G (2010) Hypomethylation of a LINE-1 promoter activates an alternate transcript of the MET oncogene in bladders with cancer. PLoS Genet 6(4):e1000917
14. Baba Y, Huttenhower C, Nosho K, Tanaka N, Shima K, Hazra A, Schernhammer ES, Hunter DJ, Giovannucci EL, Fuchs CS et al (2010) Epigenomic diversity of colorectal cancer indicated by LINE-1 methylation in a database of 869 tumors. Mol Cancer 9:125
15. Roman-Gomez J, Jimenez-Velasco A, Agirre X, Cervantes F, Sanchez J, Garate L, Barrios M, Castillejo JA, Navarro G, Colomer D et al (2005) Promoter hypomethylation of the LINE-1 retrotransposable elements activates sense/antisense transcription and marks the progression of chronic myeloid leukemia. Oncogene 24(48):7213-7223
16. Saito K, Kawakami K, Matsumoto I, Oda M, Watanabe G, Minamoto T (2010) Long interspersed nuclear element 1 hypomethylation is a marker of poor prognosis in stage IA nonsmall cell lung cancer. Clin Cancer Res 16(8):2418-2426
17. Allred DC, Mohsin SK (2000) Biological features of premalignant disease in the human breast. J Mammary Gland Biol Neoplasia 5(4):351-364
18. Dupont WD, Page DL (1985) Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 312(3):146-151
19. Hartmann LC, Sellers TA, Frost MH, Lingle WL, Degnim AC, Ghosh K, Vierkant RA, Maloney SD, Pankratz VS, Hillman DW et al (2005) Benign breast disease and the risk of breast cancer. N Engl J Med 353(3):229-237
20. O'Connell P, Pekkel V, Fuqua SA, Osborne CK, Clark GM, Allred DC (1998) Analysis of loss of heterozygosity in 399 premalignant breast lesions at 15 genetic loci. J Natl Cancer Inst 90(9):697-703
21. Maegawa S, Hinkal G, Kim HS, Shen L, Zhang L, Zhang J, Zhang N, Liang S, Donehower LA, Issa JP (2010) Widespread and tissue specific age-related DNA methylation changes in mice. Genome Res 20(3):332-340
22. Teschendorff AE, Menon U, Gentry-Maharaj A, Ramus SJ, Weisenberger DJ, Shen H, Campan M, Noushmehr H, Bell CG, Maxwell AP et al (2010) Age-dependent DNA methylation of genes that are suppressed in stem cells is a hallmark of cancer. Genome Res 20(4):440-446
23. De Kruijf EM, Van Nes JG, Sajet A, Tummers QR, Putter H, Osanto S, Speetjens FM, Smit VT, Liefers GJ, Van De Velde CJ et al (2010) The predictive value of HLA class I tumor cell expression and presence of intratumoral Tregs for chemotherapy in patients with early breast cancer. Clin Cancer Res 16(4):1272-1280
24. Van Nes JG, De Kruijf EM, Faratian D, Van De Velde CJ, Putter H, Falconer C, Smit VT, Kay C, Van De Vijver MJ, Kuppen PJ et al (2011) COX2 expression in prognosis and in prediction to endocrine therapy in early breast cancer patients. Breast Cancer Res Treat 125(3):671-685
25. Allred DC, Carlson RW, Berry DA, Burstein HJ, Edge SB, Goldstein LJ, Gown A, Hammond ME, Iglehart JD, Moench S et al (2009) NCCN Task Force report: estrogen receptor and progesterone receptor testing in breast cancer by immunohistochemistry. J Natl Compr Cancer Netw 7(Suppl 6):S1-S21 (quiz S22-23)
26. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A et al (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25(1):118-145
27. Hayes DF, Ethier S, Lippman ME (2006) New guidelines for reporting of tumor marker studies in breast cancer research and treatment: remark. Breast Cancer Res Treat 100(2):237-238
28. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM (2005) Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 23(36):9067-9072
29. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM (2006) REporting recommendations for tumor MAR-Ker prognostic studies (REMARK). Breast Cancer Res Treat 100(2):229-235
30. Sunami E, De Maat M, Vu A, Turner RR, Hoon DS (2011) LINE-1 hypomethylation during primary colon cancer progression. PLoS ONE 6(4):e18884
31. De Maat MF, Umetani N, Sunami E, Turner RR, Hoon DS (2007) Assessment of methylation events during colorectal tumor progression by absolute quantitative analysis of methylated alleles. Mol Cancer Res 5(5):461-471
32. Tanemura A, Terando AM, Sim MS, Van Hoesel AQ, De Maat MF, Morton DL, Hoon DS (2009) CpG island methylator phenotype predicts progression of malignant melanoma. Clin Cancer Res 15(5):1801-1807
33. Putter H, Fiocco M, Geskus RB (2007) Tutorial in biostatistics: competing risks and multi-state models. Stat Med 26(11):2389-2430
34. Trichopoulos D, MacMahon B, Cole P (1972) Menopause and breast cancer risk. J Natl Cancer Inst 48(3):605-613
35. Lisabeth LD, Beiser AS, Brown DL, Murabito JM, Kelly-Hayes M, Wolf PA (2009) Age at natural menopause and risk of ischemic stroke: the Framingham heart study. Stroke 40(4):1044-1049
36. Adami HO, Malker B, Holmberg L, Persson I, Stone B (1986) The relation between survival and age at diagnosis in breast cancer. N Engl J Med 315(9):559-563
37. Early Breast Cancer Trialists' Collaborative Group (1998) Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351(9114):1451-1467
38. Jatoi I, Chen BE, Anderson WF, Rosenberg PS (2007) Breast cancer mortality trends in the United States according to estrogen receptor status and age at diagnosis. J Clin Oncol 25(13):1683-1690
39. Jemal A, Ward E, Thun MJ (2007) Recent trends in breast cancer incidence rates by age and tumor characteristics among U. S. women. Breast Cancer Res 9(3):R28
40. Albain KS, Allred DC, Clark GM (1994) Breast cancer outcome and predictors of outcome: are there age differentials? J Natl Cancer Inst Monogr 16:35-42
41. Nixon AJ, Neuberg D, Hayes DF, Gelman R, Connolly JL, Schnitt S, Abner A, Recht A, Vicini F, Harris JR (1994) Relationship of patient age to pathologic features of the tumor and prognosis for patients with stage I or II breast cancer. J Clin Oncol 12(5):888-894
42. Bastiaannet E, Liefers GJ, De Craen AJ, Kuppen PJ, Van De Water W, Portielje JE, Van der Geest LG, Janssen-Heijnen ML, Dekkers OM, Van De Velde CJ et al (2010) Breast cancer in elderly compared to younger patients in the Netherlands: stage at diagnosis, treatment and survival in 127, 805 unselected patients. Breast Cancer Res Treat 124(3):801-807
43. Giordano SH, Hortobagyi GN, Kau SW, Theriault RL, Bondy ML (2005) Breast cancer treatment guidelines in older women. J Clin Oncol 23(4):783-791
44. Moinfar F (2007) Essentials of diagnostic breast pathology, vol XVI. Springer, Heidelberg
45. De Kruijf EM, Sajet A, Van Nes JG, Putter H, Smit VT, Eagle RA, Jafferji I, Trowsdale J, Liefers GJ, Van De Velde CJ et al (2012) NKG2D ligand tumor expression and association with clinical outcome in early breast cancer patients: an observational study. BMC Cancer 12(1):24
46. Pattamadilok J, Huapai N, Rattanatanyong P, Vasurattana A, Triratanachat S, Tresukosol D, Mutirangura A (2008) LINE-1 hypomethylation level as a potential prognostic factor for epithelial ovarian cancer. Int J Gynecol Cancer 18(4):711-717
47. Harris CR, Normart R, Yang Q, Stevenson E, Haffty BG, Ganesan S, Cordon-Cardo C, Levine AJ, Tang LH (2010) Association of nuclear localization of a long interspersed nuclear element-1 protein in breast tumors with poor prognostic outcomes. Genes Cancer 1(2):115-124
48. Rockwood LD, Felix K, Janz S (2004) Elevated presence of retrotransposons at sites of DNA double strand break repair in mouse models of metabolic oxidative stress and MYC-induced lymphoma. Mutat Res 548 (1-2):117-125
49. Igarashi S, Suzuki H, Niinuma T, Shimizu H, Nojima M, Iwaki H, Nobuoka T, Nishida T, Miyazaki Y, Takamaru H et al (2010) A novel correlation between LINE-1 hypomethylation and the malignancy of gastrointestinal stromal tumors. Clin Cancer Res 16(21):5114-5123
50. Kazazian HH Jr, Goodier JL (2002) LINE drive: retrotransposition and genome instability. Cell 110(3):277-280
51. Hagan CR, Rudin CM (2002) Mobile genetic element activation and genotoxic cancer therapy: potential clinical implications. Am J Pharmacogenomics 2(1):25-35